Essex Bio-Technology attends the 2022 GRC-FGF Conference, with two cutting-edge scientific research accepted by GRC
2022.05.07 Download
Hong Kong, 07 May 2022

Essex Bio-Technology Ltd (“Essex” or the “Group”, Stock Code: 1061.HK) today announced the Group attended the Gordon Research Conference on Fibroblast Growth Factors in Development and Disease (GRC-FGF) held in Lucca (Barga), LU, Italy between 1 May to 6 May with two innovative original research from Essex: “bFGF exerts a neuroprotective effect in vitro by reversing amyloid-beta oligomer toxicity in brain primary cells” and “FGF18 promotes extracellular matrix production and regulates inflammatory cytokine secretion in primary rat chondrocytes”.

GRC-FGF Conference belongs to Gordon Research Conferences (GRC) series. A biennial event, GRC-FGF attracts the world's advanced researchers in Fibroblast Growth Factor (FGF) area. It is a worldwide platform for top researchers to share their cutting-edge research related to FGF superfamily. The topic of the 2022 GRC-FGF conference is “FGF signaling: understanding function and devising therapeutic tools”.
~ End ~
About Gordon Research Conference (GRC)

The Gordon Research Conferences provide an international forum for the presentation and discussion of frontier research in the biological, chemical, physical and engineering sciences and their interfaces. Since it was founded in 1931, GRC has established a prestigious reputation for creating enduring scientific communities that advance the frontiers of research in biology, chemistry, physics, engineering, and related technologies. GRC organizes over 395 Gordon Research Conferences (GRCs) and Gordon Research Seminars (GRSs) per year, each highlighting the latest, cutting-edge research in fields ranging from physics to neurobiology, material science and engineering, to medicine.
About Fibroblast Growth Factor (FGF)

FGFs, an important member of the growth factor family, are cell signalling proteins that play a positive role in multiple cellular processes including proliferation, differentiation, cell survival, cell adhesion, motility, chemotaxis, neovasculature and homeostasis. The product(s) from Essex's FGF Technology Platform provides a therapeutic with balanced level of growth factor(s) to local damaged environment, making it a safe and effective treatment for human wounds and tissue disorders.
About Essex Bio-Technology Limited (Stock Code: 1061.HK)

Essex Bio-Technology Limited is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. Additionally, it has a portfolio of commercialised products of preservative-free unit-dose eye drops and Shilishun (适丽顺®) (Iodized Lecithin Capsules) etc.. The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 10,500 hospitals and managed directly by its 43 regional sales offices in China. Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.